Efinaconazole
- Generic Name
- Efinaconazole
- Brand Names
- Jublia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H22F2N4O
- CAS Number
- 164650-44-6
- Unique Ingredient Identifier
- J82SB7FXWB
Overview
Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.
Background
Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.
Indication
Indicated in the treatment of fungal infection of the nail, known as onychomycosis.
Associated Conditions
- Onychomycosis
Clinical Trials
FDA Approved Products
JUBLIA
Manufacturer:Bausch Health US LLC
Route:TOPICAL
Strength:100 mg in 1 mL
Approved: 2022/03/31
NDC:0187-5400
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath